Novavax Inc. (NVAX) Announces New Proprietary Process to Battle SARS
Novavax Inc. (Nasdaq: NVAX) creates novel vaccines to address a broad range of infectious diseases with its proprietary virus-like particle (VLP) technology, taking part in the rapidly growing, $13 billion global vaccine market. Today the company announced it has launched a new proprietary process to develop a vaccine candidate to fight the viral respiratory illness, Severe Acute Respiratory Syndrome (SARS). To assist in its research efforts and preclinical developments of the SARS vaccine, the company received funding from the National Institutes of Health (NIH). “Until now, it has been difficult to produce VLP vaccine candidates against SARS and other complex…